Status:

RECRUITING

Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborating Sponsors:

Comprehensive Cancer Centre The Netherlands

Conditions:

Cancer

Dermatologic Conditions

Eligibility:

All Genders

3+ years

Brief Summary

The purpose of this study is to see how skin conditions that are related to different kinds of cancer or cancer treatments affect a patient's overall well-being. Skin conditions are common in cancer p...

Eligibility Criteria

Inclusion

  • Cancer patients and survivors with a pre-existing dermatologic condition related to their underlying disease or completed/ongoing therapy for cancer, who present for assessment/management of their skin condition.
  • Male or female patients at least 3 years and older
  • NOTE: Informed Consent guidelines will be followed for minors
  • First grade adult family members, spouses, and caregivers of patients with a Grade 2 or 3 or higher dermatologic condition related to their primary cancer or cancer treatment able to provide written informed consent

Exclusion

  • Cognitive or psychiatric deficit resulting in an inability to provide written informed consent

Key Trial Info

Start Date :

November 18 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

November 1 2026

Estimated Enrollment :

1025 Patients enrolled

Trial Details

Trial ID

NCT02296450

Start Date

November 18 2014

End Date

November 1 2026

Last Update

December 19 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Memorial Sloan Kettering Cancer Center

Basking Ridge, New Jersey, United States

2

Memorial Sloan Kettering Westchester

Harrison, New York, United States, 10604

3

Memorial Sloan Kettering Suffolk- Hauppauge

Hauppauge, New York, United States, 11788

4

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065